{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T18:41:42Z","timestamp":1758393702664,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40257-022-00695-y","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T08:02:45Z","timestamp":1654329765000},"page":"593-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Author\u2019s Reply to Pestana et al. Comment on: \u201cIs There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-\u03b1 Inhibitors?\u201d"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4917","authenticated-orcid":false,"given":"Afsaneh","family":"Alavi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Raffals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"695_CR1","doi-asserted-by":"publisher","unstructured":"Pestana M, et al. Comment on: \u201cIs There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-\u03b1 Inhibitors?\u201d Am J Clin Dermatol, 2022. https:\/\/doi.org\/10.1007\/s40257-022-00694-z","DOI":"10.1007\/s40257-022-00694-z"},{"issue":"1","key":"695_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60-69.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"695_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/ced.14448","volume":"46","author":"JW Frew","year":"2021","unstructured":"Frew JW, et al. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. Clin Exp Dermatol. 2021;46(2):306\u201313.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"695_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00575-3","volume":"22","author":"T Abdalla","year":"2021","unstructured":"Abdalla T, et al. Therapeutic drug monitoring in patients with suboptimal response to adalimumab for hidradenitis suppurativa: a retrospective case series. Am J Clin Dermatol. 2021;22(2):275\u201383.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"695_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.14309\/ajg.0000000000001111","volume":"116","author":"K Papamichael","year":"2021","unstructured":"Papamichael K, et al. Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn\u2019s disease: an ACCENT-II post hoc analysis. Off J Am Coll Gastroenterol. 2021;116(5):1007.","journal-title":"Off J Am Coll Gastroenterol."},{"issue":"Suppl 3","key":"695_CR6","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106.","journal-title":"Gut"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00695-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00695-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00695-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:54:47Z","timestamp":1659113687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00695-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00695-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"type":"print","value":"1175-0561"},{"type":"electronic","value":"1179-1888"}],"subject":[],"published":{"date-parts":[[2022,6,4]]},"assertion":[{"value":"19 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Afsaneh Alavi is a consultant for AbbVie, BI, Janssen, InflaRx, Novartis, and UCB and an investigator for BI, Processa. Laura Raffals has no conflicts of interest that are directly relevant to the content of this letter.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}